Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial

Diabetes, Obesity and MetabolismEarly View RESEARCH LETTER Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial Yujuan Fan MS, Yujuan Fan MS orcid.org/0000-0003-3439-8064 Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China Department of Endocrinology and Metabolism, Minhang Hospital, Fudan University, Shanghai, ChinaSearch for more papers by this authorMingfeng Xia PhD, Mingfeng Xia PhD Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaSearch for more papers by this authorHongmei Yan PhD, Hongmei Yan PhD orcid.org/0000-0001-7341-4368 Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaSearch for more papers by this authorXiaoying Li PhD, Xiaoying Li PhD Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaSearch for more papers by this authorXinxia Chang PhD, Corresponding Author Xinxia Chang PhD chang.xinxia@zs-hospital.sh.cn Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China Correspondence Xinxia Chang, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. Email: chang.xinxia@zs-hospital.sh.cnSearch for more papers by this author Yujuan Fan MS, Yujuan Fan MS orcid.org/0000-0003-3439-8064 Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China Department of Endocrinology and Metabolism, Minhang Hospital, Fudan University, Shanghai, ChinaSearch for more papers by this authorMingfeng Xia PhD, Mingfeng Xia PhD Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaSearch for more papers by this authorHongmei Yan PhD, Hongmei Yan PhD orcid.org/0000-0001-7341-4368 Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaSearch for more papers by this authorXiaoying Li PhD, Xiaoying Li PhD Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaSearch for more papers by this authorXinxia Chang PhD, Corresponding Author Xinxia Chang PhD chang.xinxia@zs-hospital.sh.cn Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China Correspondence Xinxia Chang, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. Email: chang.xinxia@zs-hospital.sh.cnSearch for more papers by this author First published: 17 November 2023 https://doi.org/10.1111/dom.15359Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat CONFLICT OF INTEREST STATEMENT There are no conflicts of interest to disclose. Open Research DATA AVAILABILITY STATEMENT All datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request. Supporting Information Filename Description dom15359-sup-0001-Supinfo.docxWord 2007 document , 1.5 MB Data S1. Supporting Information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7: 851-861. 10.1016/S2468-1253(22)00165-0 PubMedWeb of Science®Google Scholar 2Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021; 18: 223-238. 10.1038/s41575-020-00381-6 PubMedWeb of Science®Google Scholar 3Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020; 69: 1691-1705. 10.1136/gutjnl-2020-320622 CASPubMedWeb of Science®Google Scholar 4Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016; 387: 679-690. 10.1016/S0140-6736(15)00803-X CASPubMedWeb of Science®Google Scholar 5Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021; 384: 1113-1124. 10.1056/NEJMoa2028395 CASPubMedWeb of Science®Google Scholar 64. Lifestyle management: standards of medical Care in Diabetes-2018. Diabetes Care. 2018; 41: S38-s50. 10.2337/dc18-S004 PubMedWeb of Science®Google Scholar 7Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018; 14: 390-403. 10.1038/s41574-018-0016-2 CASPubMedWeb of Science®Google Scholar 8Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019; 70: 711-724. 10.1002/hep.30429 CASPubMedWeb of Science®Google Scholar 9Gastaldelli A, Gaggini M, Daniele G, et al. Exenatide improves both hepatic and adipose tissue insulin resistance: a dynamic positron emission tomography study. Hepatology. 2016; 64: 2028-2037. 10.1002/hep.28827 CASPubMedWeb of Science®Google Scholar 10Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like Peptide-1. Cell Metab. 2018; 27: 740-756. 10.1016/j.cmet.2018.03.001 CASPubMedWeb of Science®Google Scholar 11Finer N. Weight loss interventions and nonalcoholic fatty liver disease: optimizing liver outcomes. Diabetes Obes Metab. 2022; 24(Suppl 2): 44-54. 10.1111/dom.14569 CASPubMedWeb of Science®Google Scholar 12Yan J, Yao B, Kuang H, et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology. 2019; 69: 2414-2426. 10.1002/hep.30320 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation